Umberto Pensato։ Left Ventricular Dysfunction and DOAC Benefit in ESUS
Umberto Pensato, Assistant Professor of Neurology at the Humanitas University, Research Collaborator at the University of Calgary, shared on X about a recent article by Richa Sharma et al., published in Stroke, adding:
”Super important ARCADIA post hoc!
LV dysfunction is a treatment effect modifier of DOACs for stroke prevention.
(ie DOAC benefits only in ESUS with LV dysfunction).”
Title: Apixaban and Recurrent Stroke Risk With Left Ventricular Dysfunction: A Secondary Analysis of the ARCADIA Trial
Authors: Richa Sharma, Dinesh Jillella, Cenai Zhang, Mitchell S.V. Elkind, Hooman Kamel, Marco R. Di Tullio, Richard A. Kronmal, Balaji Krishnaiah, Shadi Yaghi, W.T. Longstreth Jr, David L. Tirschwell, Alexander E. Merkler, Fadi Nahab
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 14, 2026, 16:14Susanne Lager: Isthmin-2 Emerges as an Early Predictor of Pregnancy Complications
-
Sep 14, 2026, 15:53Leonard Valentino: Advancing a New Model of Patient-Led Research
-
Sep 14, 2026, 15:48Adishwar Rao: LAAC vs Oral Anticoagulation in Atrial Fibrillation
-
Sep 14, 2026, 15:36Lesley Van Wyk: Hemolytic Anemia Quick Revision – Tips and Tricks
-
Sep 14, 2026, 15:35Maha Othman: ISTH-BAT Reference Ranges Validated Across Five Continents in Children
-
Sep 14, 2026, 15:22Meral Kayikcioglu: Why Do Women and Men Differ in LDL-C Management?
-
Sep 14, 2026, 15:22James Crowley: The Complex Role of CRP in Cardiovascular Risk and Atherosclerosis
-
Sep 14, 2026, 15:16Factor XIII Deficiency An Often-Missed Bleeding Disorder
-
Sep 14, 2026, 15:07Raffaele Piccolo: Heparin Against Jellyfish Venom?